SUNIKA - A non-interventional study with Sutent [sunitinib] in the first line treatment of renal cell carcinoma.

Trial Profile

SUNIKA - A non-interventional study with Sutent [sunitinib] in the first line treatment of renal cell carcinoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2010

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SUNIKA
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Nov 2010 Primary endpoints added as reported by ClinicalTrials.gov.
    • 10 Nov 2009 Actual patient number (356) added as reported by ClinicalTrials.gov.
    • 10 Nov 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top